Abstract
Importance Positron emission tomography (PET) biomarkers are the gold standard for detection of Alzheimer amyloid and tau in vivo. Such imaging can identify cognitively unimpaired (CU) individuals who will subsequently develop cognitive impartment (CI). Plasma biomarkers would be more practical than PET or even cerebrospinal fluid (CSF) assays in clinical settings.
Objective Assess the prognostic accuracy of plasma p-tau217 in comparison to CSF and PET biomarkers for predicting the clinical progression from CU to CI.
Design In a cohort of elderly at high risk of developing Alzheimer’s dementia (AD), we measured the proportion of CU individuals who developed CI, as predicted by Aβ (A+) and/or tau (T+) biomarker assessment from plasma, CSF, and PET. Results from each method were compared with (A-T-) reference individuals. Data were analyzed from June 2023 to April 2024.
Setting Longitudinal observational cohort.
Participants Some 228 participants from the PREVENT-AD cohort were CU at the time of biomarker assessment and had 1 - 10 years of follow-up. Plasma was available from 215 participants, CSF from 159, and amyloid- and tau-PET from 155. Ninety-three participants had assessment using all three methods (main group of interest). Progression to CI was determined by clinical consensus among physicians and neuropsychologists who were blind to plasma, CSF, PET, and MRI findings, as well as APOE genotype.
Exposures Plasma Aβ42/40 was measured using IP-MS; CSF Aβ 42/40 using Lumipulse; plasma and CSF p-tau217 using UGOT assay. Aβ-PET employed the 18F-NAV4694 ligand, and tau-PET used 18F-flortaucipir.
Main Outcome Prognostic accuracy of plasma, CSF, and PET biomarkers for predicting the development of CI in CU individuals.
Results Cox proportional hazard models indicated a greater progression rate in all A+T+ groups compared to A-T-groups (HR = 6.61 [95% CI = 2.06 – 21.17] for plasma, 3.62 [1.49 – 8.81] for CSF and 9.24 [2.34 – 36.43] for PET). The A-T+ groups were small, but also characterized with individuals who developed CI. Plasma biomarkers identified about five times more T+ than PET.
Conclusion and relevance Plasma p-tau217 assessment is a practical method for identification of persons who will develop cognitive impairment up to 10 years later.
Question Can plasma p-tau217 serve as a prognostic indicator for identifying cognitively unimpaired (CU) individuals at risk of developing cognitive impairments (CI)?
Findings In a longitudinal cohort of CU individuals with a family history of sporadic AD, almost all individuals with abnormal plasma p-tau217 concentrations developed CI within 10 years, regardless of plasma amyloid levels. Similar findings were obtained with CSF p-tau217 and tau-PET. Fluid p-tau217 biomarkers had the main advantage over PET of identifying five times more participants with elevated tau.
Meaning Elevated plasma p-tau217 levels in CU individuals strongly indicate future clinical progression
Competing Interest Statement
HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work).MS has served on advisory boards for Roche, Novo Nordisk and Servier, received speaker honoraria from Bioarctic, Eisai, Genentech, Novo Nordisk and Roche and receives research support (to the institution) from Alzpath, Bioarctic, Novo Nordisk and Roche (outside scope of submitted work). He is a co-founder of Centile Bioscience Ltd. No other disclosures were reported.
Funding Statement
The authors acknowledge all the PREVENT-AD participants and their families as well as all the PREVENT-AD team members for their time and dedication The authors would like to acknowledge Alfonso Fajardo, Ting Qiu, Mohammadali Javanray, Jonathan Gallego Rudolf, Béry Mohammediyan, Jordana Remz for providing advice on the study analyses and Jennifer Tremblay-Mercier, Louise Hudon, Christine Déry, Elisabeth Sylvian, Gabriel Jean, Nolan-Patrick Conningham for their contribution to the data collection. Lobna Almasalmeh and the Neurokemi lab at Gothenburg university for their assistance in plasma and CSF sample processing The project was funded by the Canadian Institute of Health Research (CIHR) (#438655) and Brain Canada grants. Dr.Zetterberg is a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council supported by grants from the Swedish Research Council (#202300356; #202201018 and #201902397), the European Union's Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG 71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809 2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF 21 831376 C, #ADSF 21 831381 C, #ADSF 21 831377 C, and #ADSF 24 1284328 C), the Bluefield Project, Cure Alzheimer's Fund, the Olav Thon Foundation, the Erling Persson Family Foundation, Familjen Rönströms Stiftelse, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022 0270), the European Union's Horizon 2020 research and innovation programme under the Marie Sk łodowska Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme Neurodegenerative Disease Research (JPND2021 00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI 1003). Dr. St-Onge was funded by a scholarship from the Fonds de Recherche du Quebec-Santé (FRQS). Dr.Soucy is funded by the CIHR, Brain Canada, and Biogen Canada. Dr.Poirier is funded by CIHR, the J.L Levesque Foundation, FRQS, and Natural Sciences and Engineering Research Council of Canada (NSERC) grants. Dr.Schöll receives funding from the Knut and Alice Wallenberg Foundation (Wallenberg Centre for Molecular and Translational Medicine; KAW2014 0363 and KAW 2023 0371), the Swedish Research Council (2017 02869, 2021 02678, 2021 06545 and 2023 06188), the European Union's Horizon Europe research and innovation program under grant agreement no 101132933 (AD RIDDLE) and 101112145 (PROMINENT), the National Institute of Health (R01 AG081394 01), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF agreement (ALFGBG 813971 and ALFGBG 965326), the Swedish Brain Foundation (FO2021 0311), the Swedish Alzheimer Foundation (AF 994900), the Sahlgrenska Academy at the University of Gothenburg, the Västra Götaland Region R&D (VGFOUREG 995510) and Innovation platforms, Sahlgrenska Science Park and the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Written informed consent was obtained from all participants and all research procedures were approved by the Institutional Review Board at McGill University and complied with the ethical principles of the Declaration of Helsinki. A detailed description of the PREVENT-AD cohort is available (https://pubmed.ncbi.nlm.nih.gov/34192666/)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability
Data used in the preparation of this manuscript were obtained from the Pre-symptomatic Evaluation of Experimental or Novel Treatments for Alzheimer’s Disease (PREVENT-AD). Some of the data are publicly available (https://openpreventad.loris.ca and https://registeredpreventad.loris.ca), and the remaining data can be shared upon approval by the scientific committee at the Centre for Studies on Prevention of Alzheimer’s Disease (StoP-AD) at the Douglas Mental Health University Institute. A complete listing of PREVENT-AD investigators can be found at https://preventad.loris.ca/acknowledgements/acknowledgements.php?date=2023-03-23.
